CN101031570B - Vegf受体和hgf受体信号的抑制剂 - Google Patents
Vegf受体和hgf受体信号的抑制剂 Download PDFInfo
- Publication number
- CN101031570B CN101031570B CN2005800331963A CN200580033196A CN101031570B CN 101031570 B CN101031570 B CN 101031570B CN 2005800331963 A CN2005800331963 A CN 2005800331963A CN 200580033196 A CN200580033196 A CN 200580033196A CN 101031570 B CN101031570 B CN 101031570B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- aryl
- heteroaryl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCC(C)(C)*(S(C)C1=CC(*(C)C)=CCC1I)=C(C)C Chemical compound CCC(C)(C)*(S(C)C1=CC(*(C)C)=CCC1I)=C(C)C 0.000 description 7
- VZFACCUWZGZFDB-UHFFFAOYSA-N Nc(cc1)cc(F)c1Oc1c2[s]c(CN3CCOCC3)cc2ncc1 Chemical compound Nc(cc1)cc(F)c1Oc1c2[s]c(CN3CCOCC3)cc2ncc1 VZFACCUWZGZFDB-UHFFFAOYSA-N 0.000 description 2
- BSCIYCJFOBGXLE-UHFFFAOYSA-N CC(NC(Cc1ccccc1)=O)=S Chemical compound CC(NC(Cc1ccccc1)=O)=S BSCIYCJFOBGXLE-UHFFFAOYSA-N 0.000 description 1
- CXSMHFDJLUDFQJ-UHFFFAOYSA-N CC1(C=C=[N]=C2C=C(CN3CCOCC3)SC12)Oc(ccc([N+]([O-])=O)c1)c1F Chemical compound CC1(C=C=[N]=C2C=C(CN3CCOCC3)SC12)Oc(ccc([N+]([O-])=O)c1)c1F CXSMHFDJLUDFQJ-UHFFFAOYSA-N 0.000 description 1
- WSRIWXGIDDENRS-UHFFFAOYSA-N CN(C)c(cc1)ccc1-c1cc2nccc(Oc(c(F)c3)ccc3NC(NC(Cc3ccccc3)=O)=S)c2[s]1 Chemical compound CN(C)c(cc1)ccc1-c1cc2nccc(Oc(c(F)c3)ccc3NC(NC(Cc3ccccc3)=O)=S)c2[s]1 WSRIWXGIDDENRS-UHFFFAOYSA-N 0.000 description 1
- LSLSWDHPTZERKB-UHFFFAOYSA-N COC(c1cc(nccc2Oc(ccc(N)c3)c3F)c2[s]1)=O Chemical compound COC(c1cc(nccc2Oc(ccc(N)c3)c3F)c2[s]1)=O LSLSWDHPTZERKB-UHFFFAOYSA-N 0.000 description 1
- HWTXIWLPSDZEKV-UHFFFAOYSA-N COC(c1cc2nccc(Oc(ccc(NC(NC(Cc3ccccc3)=O)=S)c3)c3F)c2[s]1)=O Chemical compound COC(c1cc2nccc(Oc(ccc(NC(NC(Cc3ccccc3)=O)=S)c3)c3F)c2[s]1)=O HWTXIWLPSDZEKV-UHFFFAOYSA-N 0.000 description 1
- KYLDWUCCZGMRQZ-UHFFFAOYSA-N CS(c1cc(ncnc2Oc(ccc(N)c3)c3F)c2[s]1)=O Chemical compound CS(c1cc(ncnc2Oc(ccc(N)c3)c3F)c2[s]1)=O KYLDWUCCZGMRQZ-UHFFFAOYSA-N 0.000 description 1
- JRQGQSZTCIACTE-UHFFFAOYSA-N CS(c1cc(ncnc2Oc(ccc(NC(NC(Cc3ccccc3)=O)=S)c3)c3F)c2[s]1)=O Chemical compound CS(c1cc(ncnc2Oc(ccc(NC(NC(Cc3ccccc3)=O)=S)c3)c3F)c2[s]1)=O JRQGQSZTCIACTE-UHFFFAOYSA-N 0.000 description 1
- OBEYCNBHXXEOOM-UHFFFAOYSA-N CSc1cc(ncnc2Oc(ccc([N+]([O-])=O)c3)c3F)c2[s]1 Chemical compound CSc1cc(ncnc2Oc(ccc([N+]([O-])=O)c3)c3F)c2[s]1 OBEYCNBHXXEOOM-UHFFFAOYSA-N 0.000 description 1
- DUFSUUJJSWCKKU-UHFFFAOYSA-N Cc1cc2ncnc(Oc(ccc([N+]([O-])=O)c3)c3F)c2[s]1 Chemical compound Cc1cc2ncnc(Oc(ccc([N+]([O-])=O)c3)c3F)c2[s]1 DUFSUUJJSWCKKU-UHFFFAOYSA-N 0.000 description 1
- MLCYCDGBGIYUFG-UHFFFAOYSA-N Cc1ccnc2c1[s]c(CN1CCOCC1)c2 Chemical compound Cc1ccnc2c1[s]c(CN1CCOCC1)c2 MLCYCDGBGIYUFG-UHFFFAOYSA-N 0.000 description 1
- VCXUMOHCJBPHCL-UHFFFAOYSA-N O=C(Cc1ccccc1)NC(Nc(cc1)cc(F)c1Oc1ccnc2c1[s]c(-c1cc(CN3CCOCC3)ccc1)c2)=S Chemical compound O=C(Cc1ccccc1)NC(Nc(cc1)cc(F)c1Oc1ccnc2c1[s]c(-c1cc(CN3CCOCC3)ccc1)c2)=S VCXUMOHCJBPHCL-UHFFFAOYSA-N 0.000 description 1
- GCOQDKNKQAPKGU-UHFFFAOYSA-N O=Cc1cc2nccc(Cl)c2[s]1 Chemical compound O=Cc1cc2nccc(Cl)c2[s]1 GCOQDKNKQAPKGU-UHFFFAOYSA-N 0.000 description 1
- ORPHLVJBJOCHBR-UHFFFAOYSA-N [O-][N+](c(cc1F)ccc1O)=O Chemical compound [O-][N+](c(cc1F)ccc1O)=O ORPHLVJBJOCHBR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59291304P | 2004-07-30 | 2004-07-30 | |
| US60/592,913 | 2004-07-30 | ||
| US68303805P | 2005-05-20 | 2005-05-20 | |
| US60/683,038 | 2005-05-20 | ||
| PCT/CA2005/001177 WO2006010264A1 (en) | 2004-07-30 | 2005-07-28 | Inhibitors of vegf receptor and hgf receptor signaling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101031570A CN101031570A (zh) | 2007-09-05 |
| CN101031570B true CN101031570B (zh) | 2012-09-05 |
Family
ID=35785877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005800331963A Expired - Fee Related CN101031570B (zh) | 2004-07-30 | 2005-07-28 | Vegf受体和hgf受体信号的抑制剂 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7772247B2 (https=) |
| EP (1) | EP1781664B1 (https=) |
| JP (1) | JP5096142B2 (https=) |
| KR (1) | KR101257343B1 (https=) |
| CN (1) | CN101031570B (https=) |
| AU (1) | AU2005266803B2 (https=) |
| BR (1) | BRPI0513982A (https=) |
| CA (1) | CA2573538C (https=) |
| ES (1) | ES2438017T3 (https=) |
| IL (1) | IL180788A0 (https=) |
| MX (1) | MX2007001216A (https=) |
| RU (1) | RU2007107167A (https=) |
| WO (1) | WO2006010264A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2569016C (en) * | 2004-06-02 | 2012-11-27 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| ES2438017T3 (es) | 2004-07-30 | 2014-01-15 | Methylgene Inc. | Inhibidores de la señalización del receptor del VEGF y del receptor del HGF |
| AU2006229343A1 (en) * | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency |
| JP2008536932A (ja) * | 2005-04-18 | 2008-09-11 | サイード・アール・カーン | チューブリン重合阻害剤：ボンゾイルフェニル尿素（ｂｐｕ）硫黄類似体の設計及び合成 |
| KR101378716B1 (ko) * | 2005-05-20 | 2014-04-10 | 메틸진 인코포레이티드 | Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제 |
| AU2006313456B2 (en) | 2005-05-20 | 2011-06-23 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
| TW200730527A (en) * | 2005-12-02 | 2007-08-16 | Takeda Pharmaceuticals Co | Fused heterocyclic compound |
| JP2009526761A (ja) * | 2006-01-30 | 2009-07-23 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環式チオフェン化合物および使用の方法 |
| AR060061A1 (es) * | 2006-03-22 | 2008-05-21 | Methylgene Inc | Inhibidores de la actividad de la proteina tirosina quinasa |
| JP2009539878A (ja) * | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
| ES2593279T3 (es) | 2007-08-29 | 2016-12-07 | Methylgene Inc. | Procesos e intermedios para preparar inhibidores de cinasa heterocíclicos condensados |
| PL2183254T3 (pl) | 2007-08-29 | 2017-10-31 | Methylgene Inc | Inhibitory aktywności białkowej kinazy tyrozynowej |
| NZ588355A (en) | 2008-03-05 | 2012-03-30 | Methylgene Inc | Inhibitors of protein tyrosine kinase activity |
| ES2599458T3 (es) * | 2008-10-14 | 2017-02-01 | Sunshine Lake Pharma Co., Ltd. | Compuestos y métodos de uso |
| EP2408300B1 (en) * | 2009-03-21 | 2016-05-11 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
| JP2013525286A (ja) * | 2010-04-16 | 2013-06-20 | メチルジーン・インコーポレイテッド | タンパク質チロシンキナーゼ活性の阻害剤 |
| US20130225581A1 (en) | 2010-07-16 | 2013-08-29 | Kyowa Hakko Kirin Co., Ltd | Nitrogen-containing aromatic heterocyclic derivative |
| TW201217387A (en) | 2010-09-15 | 2012-05-01 | Hoffmann La Roche | Azabenzothiazole compounds, compositions and methods of use |
| RU2568258C2 (ru) | 2011-02-28 | 2015-11-20 | Саншайн Лейк Фарма Ко., Лтд | Замещенные соединения хинолина и способы их использования |
| HUE056194T2 (hu) | 2012-02-21 | 2022-01-28 | Towa Pharmaceutical Europe S L | Dabigatrán-etexilát orális gyógyszerészeti készítményei |
| TWI520962B (zh) * | 2012-06-29 | 2016-02-11 | As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives | |
| JP6342392B2 (ja) | 2012-07-28 | 2018-06-13 | カリター・サイエンシーズ・エルエルシー | 置換型ピラゾロン化合物及び使用方法 |
| TWI574962B (zh) | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途 |
| MX2015010700A (es) | 2013-02-21 | 2017-01-23 | Calitor Sciences Llc | Compuestos heteroaromaticos como moduladores de la p13 cinasa. |
| RS58361B1 (sr) * | 2013-07-31 | 2019-03-29 | Merck Patent Gmbh | Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba |
| US10308658B2 (en) | 2015-10-19 | 2019-06-04 | Sunshine Lake Pharma Co., Ltd. | Salt of EGFR inhibitor, crystalline form and uses thereof |
| EP3646887A4 (en) | 2017-06-30 | 2021-03-24 | Korea Advanced Institute of Science and Technology | CONJUGATE OF VEGF GRAB PROTEIN AND MEDICINAL PRODUCTS AND USES THEREOF |
| US11623923B2 (en) | 2017-11-24 | 2023-04-11 | Medshine Discovery, Inc. | Uracil compound as c-MET/AXL inhibitor |
| WO2020132384A1 (en) | 2018-12-21 | 2020-06-25 | Celgene Corporation | Thienopyridine inhibitors of ripk2 |
| US20250188147A1 (en) | 2022-03-04 | 2025-06-12 | Panalos Bioscience, Inc. | Composition for combi-therapy comprising vegf-grab and pd-1 or pd-l1 antagonist |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1280580A (zh) * | 1997-11-11 | 2001-01-17 | 辉瑞产品公司 | 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物 |
| CN101248080A (zh) * | 2005-05-20 | 2008-08-20 | 梅赛尔基因股份有限公司 | Vegf受体和hgf受体信号的抑制剂 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107300A (en) * | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| AU4231299A (en) | 1998-06-04 | 1999-12-20 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
| WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| BR0111377A (pt) | 2000-06-06 | 2003-06-03 | Pfizer Prod Inc | Derivados de tiofeno úteis como agentes anticancerìgenos |
| US20020004511A1 (en) * | 2000-06-28 | 2002-01-10 | Luzzio Michael Joseph | Thiophene derivatives useful as anticancer agents |
| AU9598601A (en) * | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| WO2003000194A2 (en) | 2001-06-21 | 2003-01-03 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| AU2002313249B2 (en) * | 2001-06-22 | 2008-08-21 | Kirin Pharma Kabushiki Kaisha | Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same |
| GB0119249D0 (en) * | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| AU2003206068A1 (en) | 2002-03-01 | 2003-09-16 | Pfizer Inc. | Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents |
| US20030199525A1 (en) * | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
| CL2003002287A1 (es) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| DE10335598A1 (de) | 2003-08-04 | 2005-02-24 | Robert Bosch Gmbh | Pedal-Vorrichtung für Kraftfahrzeuge |
| ES2314444T3 (es) | 2003-08-29 | 2009-03-16 | Pfizer Inc. | Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos. |
| WO2005052872A1 (en) * | 2003-11-21 | 2005-06-09 | Facil, Llc | Financial transaction system and method |
| JP2007518823A (ja) * | 2004-01-23 | 2007-07-12 | アムゲン インコーポレイテッド | キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途 |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) * | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| WO2005121125A1 (en) | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
| US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7977345B2 (en) | 2004-07-02 | 2011-07-12 | Exelixis, Inc. | c-MET modulators and method of use |
| MX2007000631A (es) | 2004-07-16 | 2007-03-30 | Sunesis Pharmaceuticals Inc | Tienopirimidinas utiles como inhibidores de aurora cinasa. |
| ES2438017T3 (es) | 2004-07-30 | 2014-01-15 | Methylgene Inc. | Inhibidores de la señalización del receptor del VEGF y del receptor del HGF |
| AU2006229343A1 (en) | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| KR101378716B1 (ko) | 2005-05-20 | 2014-04-10 | 메틸진 인코포레이티드 | Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제 |
-
2005
- 2005-07-28 ES ES05770304.3T patent/ES2438017T3/es not_active Expired - Lifetime
- 2005-07-28 AU AU2005266803A patent/AU2005266803B2/en not_active Ceased
- 2005-07-28 CA CA2573538A patent/CA2573538C/en not_active Expired - Fee Related
- 2005-07-28 KR KR1020077005060A patent/KR101257343B1/ko not_active Expired - Fee Related
- 2005-07-28 EP EP05770304.3A patent/EP1781664B1/en not_active Expired - Lifetime
- 2005-07-28 WO PCT/CA2005/001177 patent/WO2006010264A1/en not_active Ceased
- 2005-07-28 CN CN2005800331963A patent/CN101031570B/zh not_active Expired - Fee Related
- 2005-07-28 US US11/191,617 patent/US7772247B2/en active Active
- 2005-07-28 BR BRPI0513982-1A patent/BRPI0513982A/pt not_active Application Discontinuation
- 2005-07-28 JP JP2007522886A patent/JP5096142B2/ja not_active Expired - Fee Related
- 2005-07-28 MX MX2007001216A patent/MX2007001216A/es active IP Right Grant
- 2005-07-28 RU RU2007107167/04A patent/RU2007107167A/ru not_active Application Discontinuation
-
2007
- 2007-01-18 IL IL180788A patent/IL180788A0/en unknown
-
2010
- 2010-05-06 US US12/775,090 patent/US8470850B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1280580A (zh) * | 1997-11-11 | 2001-01-17 | 辉瑞产品公司 | 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物 |
| CN101248080A (zh) * | 2005-05-20 | 2008-08-20 | 梅赛尔基因股份有限公司 | Vegf受体和hgf受体信号的抑制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005266803B2 (en) | 2011-10-27 |
| US20100216766A1 (en) | 2010-08-26 |
| JP5096142B2 (ja) | 2012-12-12 |
| MX2007001216A (es) | 2007-03-23 |
| KR101257343B1 (ko) | 2013-04-23 |
| WO2006010264A1 (en) | 2006-02-02 |
| US20060074056A1 (en) | 2006-04-06 |
| IL180788A0 (en) | 2007-06-03 |
| BRPI0513982A (pt) | 2007-11-27 |
| EP1781664A1 (en) | 2007-05-09 |
| EP1781664B1 (en) | 2013-09-04 |
| ES2438017T3 (es) | 2014-01-15 |
| KR20070051876A (ko) | 2007-05-18 |
| US7772247B2 (en) | 2010-08-10 |
| EP1781664A4 (en) | 2010-06-02 |
| AU2005266803A1 (en) | 2006-02-02 |
| JP2008508192A (ja) | 2008-03-21 |
| CA2573538C (en) | 2014-11-25 |
| US8470850B2 (en) | 2013-06-25 |
| RU2007107167A (ru) | 2008-09-10 |
| CA2573538A1 (en) | 2006-02-02 |
| CN101031570A (zh) | 2007-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101031570B (zh) | Vegf受体和hgf受体信号的抑制剂 | |
| CN101248080B (zh) | Vegf受体和hgf受体信号的抑制剂 | |
| CN105777776B (zh) | 蛋白酪氨酸激酶活性的抑制剂 | |
| AU747920B2 (en) | Bicyclic pyridine and pyrimidine derivatives as neuropeptide Y receptor antagonists | |
| TWI525093B (zh) | 用作為３'磷酸肌醇依賴性激酶１（ｐｄｋ１）抑制劑之雜環化合物 | |
| CA2564085C (en) | Heterocyclic amide compound and use thereof as an mmp-13 inhibitor | |
| CN1823071B (zh) | 用作钾通道抑制剂的噻吩并嘧啶衍生物 | |
| PT1591446E (pt) | Compostos de tienopirimidina e sua utilização | |
| KR100963644B1 (ko) | 피라졸로피리미딘온 유도체 및 그의 제조방법 | |
| CN101796055A (zh) | Vegf受体和hgf受体信号的抑制剂 | |
| MXPA05001389A (es) | Piridinas y pirimidinas condensadas con actividad tie2 (tek). | |
| WO2014106800A2 (en) | Substituted 2-amino pyrimidine derivatives as kinase inhibitors | |
| CN108191837A (zh) | PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用 | |
| CA2192283A1 (en) | Prolactin production inhibitory agent | |
| CN101160316A (zh) | 适合用作aurora激酶抑制剂的噻吩并嘧啶 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: CANADA CO., LTD., 7503547 Free format text: FORMER OWNER: 9222-9129 QUEBEC CO., LTD. Effective date: 20110113 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20110113 Address after: Quebec Applicant after: 7503547 Canada Company Address before: Quebec Applicant before: 9222-9129 Quebec Corporation |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120905 Termination date: 20200728 |